237 related articles for article (PubMed ID: 19393849)
1. A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib.
Derks M; Fowler S; Kuhlmann O
Clin Ther; 2009 Mar; 31(3):586-99. PubMed ID: 19393849
[TBL] [Abstract][Full Text] [Related]
2. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
3. Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.
Derks M; Kawamura H; Abt M; Meneses-Lorente G; Phelan M; Ishikawa T
Clin Ther; 2011 Jun; 33(6):754-65. PubMed ID: 21704240
[TBL] [Abstract][Full Text] [Related]
4. Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions.
Derks M; Abt M; Phelan M; Turnbull L; Meneses-Lorente G; Bech N; White AM; Parr G
J Clin Pharmacol; 2010 Oct; 50(10):1188-201. PubMed ID: 20489031
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
[TBL] [Abstract][Full Text] [Related]
6. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.
Derks M; Fowler S; Kuhlmann O
Curr Med Res Opin; 2009 Apr; 25(4):891-902. PubMed ID: 19245299
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers.
Shaik MN; LaBadie RR; Rudin D; Levin WJ
Cancer Chemother Pharmacol; 2014 Aug; 74(2):411-8. PubMed ID: 24944041
[TBL] [Abstract][Full Text] [Related]
9. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
Noh YH; Lim HS; Jin SJ; Kim MJ; Kim YH; Sung HR; Choi HY; Bae KS
Clin Ther; 2012 May; 34(5):1182-94. PubMed ID: 22534255
[TBL] [Abstract][Full Text] [Related]
10. The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study.
Shin KH; Kim BH; Kim TE; Kim JW; Yi S; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Dec; 31(12):3009-20. PubMed ID: 20110038
[TBL] [Abstract][Full Text] [Related]
11. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin.
Derks M; Abt M; Parr G; Meneses-Lorente G; Young AM; Phelan M
Expert Opin Investig Drugs; 2010 Oct; 19(10):1135-45. PubMed ID: 20738227
[TBL] [Abstract][Full Text] [Related]
12. Effect of coadministered ketoconazole, a strong cytochrome P450 3A4 enzyme inhibitor, on the pharmacokinetics of ciclesonide and its active metabolite desisobutyryl-ciclesonide.
Böhmer GM; Drollmann A; Gleiter CH; Nave R
Clin Pharmacokinet; 2008; 47(5):343-9. PubMed ID: 18399715
[TBL] [Abstract][Full Text] [Related]
13. Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Machiels JP; Staddon A; Herremans C; Keung C; Bernard A; Phelps C; Khokhar NZ; Knoblauch R; Parekh TV; Dirix L; Sharma S
Cancer Chemother Pharmacol; 2014 Oct; 74(4):729-37. PubMed ID: 25100135
[TBL] [Abstract][Full Text] [Related]
14. Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibe.
Derks M; Abt M; Phelan M
Br J Clin Pharmacol; 2010 Dec; 70(6):825-33. PubMed ID: 21175438
[TBL] [Abstract][Full Text] [Related]
15. Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing.
Derks M; Abt M; Mwangi A; Meneses-Lorente G
Eur J Clin Pharmacol; 2010 Aug; 66(8):775-83. PubMed ID: 20521033
[TBL] [Abstract][Full Text] [Related]
16. Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Cotreau MM; Siebers NM; Miller J; Strahs AL; Slichenmyer W
Clin Pharmacol Drug Dev; 2015 Mar; 4(2):137-42. PubMed ID: 27128217
[TBL] [Abstract][Full Text] [Related]
17. Effect of hepatic and renal impairment on the pharmacokinetics of dalcetrapib: altered distribution of the active thiol?
Phelan M; Anzures-Cabrera J; Carlile DJ; Rowell L; Kuhlmann O; Arold G; Robson R; Bentley D
Clin Pharmacokinet; 2013 Apr; 52(4):255-65. PubMed ID: 23400900
[TBL] [Abstract][Full Text] [Related]
18. An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
Tomkinson HK; Kemp JV; Wollseifen T; Morris T; Oliver SD
Clin Ther; 2010 Jul; 32(7):1372-86. PubMed ID: 20678684
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults.
Townsend R; Dietz A; Hale C; Akhtar S; Kowalski D; Lademacher C; Lasseter K; Pearlman H; Rammelsberg D; Schmitt-Hoffmann A; Yamazaki T; Desai A
Clin Pharmacol Drug Dev; 2017 Jan; 6(1):44-53. PubMed ID: 27273461
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein.
Groenendaal D; Strabach G; Garcia-Hernandez A; Kadokura T; Heeringa M; Mol R; Eltink C; Onkels H
Clin Pharmacol Drug Dev; 2014 May; 3(3):194-201. PubMed ID: 27128609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
